An announcement of a deal could be made as soon as Monday, The New York Times reported Saturday, citing unidentified "people briefed on the matter."
But " the talks could still fall apart before getting to the finish line," The Wall Street Journal reported Saturday, citing an unidentified person familiar with the matter.
If the deal -- said to be worth $125 a share for Onyx shareholders -- is completed, Amgen would gain full rights to Kyprolis, a new drug to treat multiple myeloma, Reuters reported. The drug could reach peak sales of more than $2 billion a year, the news agency said, citing analysts.A spokesman for Amgen told TheStreet.com that his company had no comment. A similar response was received from a spokeswoman for Onyx.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts